Biogen | BIIB - Equity Capital And Reserves


Biogen reported $18.21B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Bayer EUR 29.7B 799M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 6.59B 583.4M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025